ASH 2024 | Venetoclax plus azacitidine for newly diagnosed younger AML

So with the venetoclax plus azacitidine regimen in younger fit AML patients newly diagnosed, the intention was really to give them this regimen that was officially designed for older unfit patients on the logic that there are certain patients for whom this is a more effective therapy regardless of their fitness for intensive induction chemotherapy. And so this is the product of several years of work. This clinical trial has been going on for quite a while and we enrolled 36 patients to receive this lower-intensity regimen and these are patients that would have been eligible for receiving intensive induction chemotherapy but opted not to do that because their disease biology suggested they might have a better response to the venetoclax-based regimen. And so we’re very happy with the results. We’re seeing high response rates in this population with a very good long-term overall survival where most of the patients are intended to go to a transplant after this therapy. So I think the hope is that this is proof that even patients who might be eligible for intensive induction chemotherapy might be better off getting a venetoclax-based regimen and that’s you know what we’re going to discuss in the session.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.